Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2020

01-09-2020 | Esophageal Cancer | Gastrointestinal Oncology

Salvage Esophagectomy for Residual Tumor After Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Invading the Neighboring Organs: Is it a Feasible Choice?

Author: Masayuki Watanabe, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 9/2020

Login to get access

Excerpt

Treatment of locally advanced esophageal cancer invading the neighboring organs is challenging. Among the two major histologic subtypes, adenocarcinoma, most often located in the lower esophagus, can invade the descending aorta, lung, and pericardium. Meanwhile, squamous cell carcinoma (SCC), located predominantly in the middle and upper esophagus, is more likely to invade the trachea, bronchus, and aortic arch. For patients who present with extension into such vital organs, definitive chemoradiotherapy (dCRT) is indicated as the standard choice. For those with SCC, a complete response (CR) is often achieved, even among those with initially unresectable disease. This leads to the ongoing discussion of whether there is room for surgical treatment of residual tumor after dCRT. …
Literature
2.
go back to reference Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.CrossRef Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.CrossRef
3.
go back to reference de Manzoni G, Pedrazzani C, Pasini F, et al. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007;95:261–6.CrossRef de Manzoni G, Pedrazzani C, Pasini F, et al. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007;95:261–6.CrossRef
4.
go back to reference Ohkura Y, Ueno M, Iizuka T, Udagawa H. Prognostic Factors and Appropriate Lymph Node Dissection in Salvage Esophagectomy for Locally Advanced T4 Esophageal Cancer. Ann Surg Oncol. 2019;26:209–16.CrossRef Ohkura Y, Ueno M, Iizuka T, Udagawa H. Prognostic Factors and Appropriate Lymph Node Dissection in Salvage Esophagectomy for Locally Advanced T4 Esophageal Cancer. Ann Surg Oncol. 2019;26:209–16.CrossRef
5.
go back to reference Okamura A, Hayami M, Kozuki R, et al. Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Esophagus. 2020;17:59–66.CrossRef Okamura A, Hayami M, Kozuki R, et al. Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Esophagus. 2020;17:59–66.CrossRef
6.
go back to reference Noordman BJ, Apaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19:965–74.CrossRef Noordman BJ, Apaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19:965–74.CrossRef
7.
go back to reference Ferri L. Clinical T4b esophageal cancer: can we make an ‘unresectable’ tumours resectable? Ann Surg Oncol. 2020;27:329–30.CrossRef Ferri L. Clinical T4b esophageal cancer: can we make an ‘unresectable’ tumours resectable? Ann Surg Oncol. 2020;27:329–30.CrossRef
8.
go back to reference Nakajima M, Muroi H, Kikuchi M, et al. Salvage esophagectomy combined with partial aortic wall resection following thoracic endovascular aortic repair. Gen Thorac Cardiovasc Surg. 2018;66:736–43.CrossRef Nakajima M, Muroi H, Kikuchi M, et al. Salvage esophagectomy combined with partial aortic wall resection following thoracic endovascular aortic repair. Gen Thorac Cardiovasc Surg. 2018;66:736–43.CrossRef
9.
go back to reference Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115:1328–34.CrossRef Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115:1328–34.CrossRef
10.
go back to reference Yokota T, Kato K, Hamamoto Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27:460–7.CrossRef Yokota T, Kato K, Hamamoto Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27:460–7.CrossRef
11.
go back to reference Terada M, Hara H, Daiko H, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol. 2019;49:1055–60.CrossRef Terada M, Hara H, Daiko H, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol. 2019;49:1055–60.CrossRef
Metadata
Title
Salvage Esophagectomy for Residual Tumor After Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Invading the Neighboring Organs: Is it a Feasible Choice?
Author
Masayuki Watanabe, MD, PhD, FACS
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08571-x

Other articles of this Issue 9/2020

Annals of Surgical Oncology 9/2020 Go to the issue